FP-025 is under clinical development by Foresee Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect FP-025’s likelihood of approval (LoA) and phase transition for Asthma took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 06 Jun 2022 increased FP-025’s Phase Transition Success Rate (PTSR) for Chronic Obstructive Pulmonary Disease (COPD).
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their FP-025 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
FP-025 is under development for the treatment of house dust mite (HDM)-allergic asthma, chronic obstructive pulmonary disease (COPD) and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through oral route. The therapeutic candidate is being developed based on stabilized injectable formulation (SIF) platform technology. It acts by selectively targeting MMP-12 enzyme. It was also under development for the treatment of acute lung injury, non-alcoholic steatohepatitis and wound healing.
It was under development for the treatment of covid 19 with associated acute respiratory distress syndrome (ARDS).
Foresee Pharmaceuticals overview
Foresee Pharmaceuticals (FP) is a clinical-stage pharmaceutical company. It focuses on developing drugs for unmet medical needs. The company’s product portfolio comprises FP-001, for prostate cancer, FP-002, for acromegaly and carcinoid tumors, FP-025, for asthma and chronic obstructive pulmonary disease, FP-020, for Alport syndrome and FP-008, for diabetic retinopathy. It harnesses the stabilized injectable formulation (SIF) platform technology to develop controlled release drug delivery systems for peptides, small molecules and proteins. The company works in collaboration with ScinoPharm and Pierre Fabre to research and develop its product portfolio. It has operational presence in Taiwan and the US. FP is headquartered in Taipei, Taiwan.
Quick View FP-025 LOA Data
|Highest Development Stage|